ストックスクリーナーアプリを入手
12.18
3.49%
-0.44
アフターアワーズ：
12.18
前日終値:
$12.62
開ける：
$12.62
24時間の取引高:
628.26K
Relative Volume:
0.67
時価総額：
$760.73M
収益：
-
当期純損益:
$-69.71M
株価収益率:
-10.21
EPS:
-1.1935
ネットキャッシュフロー:
$-54.12M
1週間 パフォーマンス:
+3.40%
1か月 パフォーマンス:
-15.83%
6か月 パフォーマンス:
+19.29%
1年 パフォーマンス:
+214.73%
1日の値動き範囲:
$12.06
$13.36
1週間の範囲:
$11.45
$13.36
52週間の値動き範囲:
$3.77
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
名前
Design Therapeutics Inc
セクター
電話
858-293-4900
住所
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
12.18 | 741.99M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | Jefferies | Buy |
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-12-03 | 開始されました | Craig Hallum | Buy |
| 2025-12-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-05-04 | アップグレード | Goldman | Sell → Neutral |
| 2022-06-10 | 開始されました | Wedbush | Outperform |
| 2022-05-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-19 | 開始されました | Goldman | Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-20 | 開始されました | Piper Sandler | Overweight |
| 2021-04-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Design Therapeutics Inc (DSGN) 最新ニュース
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Design Therapeutics Inc (DSGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Design Therapeutics, Inc. Revenue Breakdown – NASDAQ:DSGN - TradingView
DSGN|Design Therapeutics Inc|Price:11.780|Chg%:+0.150 - TradingKey
Edgewise Therapeutics, Inc. (EWTX) options chain - Yahoo Finance Singapore
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate - Moomoo
Fuchs Dystrophy Pipeline 2026: Therapies Under Investigation, - openPR.com
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history - Yahoo Finance UK
Cellares and Papillon partner for PPL-001 manufacturing automation - Yahoo Finance
Design Therapeutics (DSGN) Q1 2026 earnings summary - Quartr
Design Therapeutics (DSGN) Leerink Global Healthcare Conference 2026 Summary - Quartr
Design Therapeutics (DSGN) Jefferies London Healthcare Conference 2024 Summary - Quartr
Design Therapeutics (DSGN) Proxy filing Summary - Quartr
Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN
Design Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Shares as Investors Focus on Pipeline ProgressFinancial Health Score - dars.gov.et
DSGN Q1 2026 Earnings: EPS Surprises to the Upside Amid Ongoing Pipeline DevelopmentEPS Surprise History - dars.gov.et
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien - Barchart.com
Myotonic Dystrophy Market Expected to Experience Accelerated - openPR.com
Design Therapeutics (DSGN) Jefferies Global Healthcare Conference 2025 Summary - Quartr
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire
If You Invested $1,000 in Design Therapeutics, Inc. (DSGN) - Stock Titan
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
Cantor Fitzgerald reiterates Design Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Design Therapeutics stock rating By Investing.com - Investing.com Nigeria
Design Therapeutics stock rises on Phase 1 trial dosing start - Investing.com
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com - Investing.com Nigeria
Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com - Investing.com South Africa
Design Therapeutics begins dosing DM1 drug in phase 1 trial - Investing.com
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - The Manila Times
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Smaller-than-Expected Loss Lifts Shares 5.28%Segment Revenue Breakdown - dars.gov.et
Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2000 Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark - marketscreener.com
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug - Benzinga
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000 Growth Benchmark - marketscreener.com
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Sahm
Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN) - TradingView
Design Therapeutics, Inc. Actuals & Estimates (BOATS:DSGN) - TradingView
DSGN Forecast — Price Target — Prediction for 2027 - TradingView
Design Therapeutics Inc (DSGN) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):